|1.||Walsh, Thomas J: 17 articles (08/2015 - 01/2002)|
|2.||Maertens, Johan: 14 articles (10/2015 - 11/2002)|
|3.||Petraitiene, Ruta: 11 articles (08/2015 - 01/2002)|
|4.||Petraitis, Vidmantas: 9 articles (08/2015 - 01/2002)|
|5.||Lagrou, Katrien: 8 articles (05/2015 - 09/2004)|
|6.||Wheat, L Joseph: 8 articles (01/2015 - 06/2007)|
|7.||Wingard, John R: 8 articles (01/2015 - 02/2007)|
|8.||Bacher, John: 7 articles (11/2010 - 01/2002)|
|9.||Cuenca-Estrella, Manuel: 6 articles (02/2015 - 12/2006)|
|10.||Nguyen, M Hong: 6 articles (01/2015 - 06/2007)|
12/01/2013 - "Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis."
01/01/2015 - "The Platelia Aspergillus Ag assay (Bio-Rad) is designed for detecting Aspergillus galactomannan (GM) and is widely used for diagnosing invasive aspergillosis but is hampered by variable occurrences of unreproducible positive results. "
02/01/2014 - "Nowadays, the galactomannan (GM) assay has been widely used as an indication of invasive aspergillosis, even though the test is known to generate false-positive results. "
09/01/2003 - "Once accepted galactomannan test as a diagnostic criterium for invasive aspergillosis knowing potential causes of false positive results is of paramount importance."
07/01/2013 - "Diagnostic efficacy of Galactomannan (GM) assay for invasive aspergillosis (IA) is variably reported. "
06/01/2004 - "This suggests that the PCR and galactomannan assays, previously suggested as useful in the management of invasive fungal infections in neutropenic haematological patients, may be suitable for application to a broad range of clinical situations and sample types."
03/01/2012 - "Nine of 11 hematological patients with disseminated/deep-seated Fusarium infection tested at least twice for Aspergillus galactomannan (GM) had repeated positive results in the absence of Aspergillus isolation in culture. "
04/01/2009 - "[Detection of 1,3-beta-D glucan for diagnosis of invasive fungal infections in hematooncological patients: usefulness for screening of invasive mycosis and for confirmation of galactomannan positive results]."
01/01/2012 - "In this study, we investigated if a recently developed β-galactomannan (βGM) had a similar protective role compared to Saccharomyces cerevisiae var. Boulardii (Scb), a proven probiotic, in the context of enterotoxigenic Escherichia coli (ETEC) infection. "
01/01/2015 - "Diagnosis of this infection frequently employs detection of the circulating galactomannan in the patient serum using enzyme immunoassay (EIA), a highly sensitive and specific system. "
|3.||Invasive Pulmonary Aspergillosis
04/01/2000 - "It was concluded that, in this model, quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis."
04/01/2000 - "Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model."
07/01/2008 - "Fungal burden and therapeutic efficacy were assessed by survival, quantitative culture (CFU counts), galactomannan enzyme immunoassay (GM-EIA), and quantitative PCR (qPCR) in a new guinea pig model of invasive pulmonary aspergillosis using an aerosol challenge. "
06/01/2014 - "Galactomannan detection in bronchoalveolar lavage (BAL) fluid samples (GM test) is currently considered the gold standard test for diagnosing invasive pulmonary aspergillosis (IPA). "
02/01/2009 - "Therefore, we evaluate the value of serum galactomannan assay in the diagnosis of pediatric invasive pulmonary aspergillosis in this study. "
11/01/2014 - "No significant differences were observed for the incidence of probable or proven IFD, positive galactomannan tests, persistent febrile neutropenia, duration of hospitalization and overall mortality. "
11/01/2014 - "Endpoints were occurrence of breakthrough probable/proven IFD under prophylaxis, incidence and duration of persistent febrile neutropenia, incidence of unspecific pneumonic infiltrates, possible IFD, positive galactomannan tests, as well as fungal-free and overall survival. "
05/01/2008 - "Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management."
01/01/2008 - "Cross-sectional studies, case-control designs and consecutive series of patients assessing the diagnostic accuracy of galactomannan detection for the diagnosis of IA in patients with neutropenia or patients whose neutrophils are functionally compromised were included. "
06/01/2015 - "Potential of polymerase chain reaction and galactomannan for the diagnosis of invasive aspergillosis in patients with febrile neutropenia."
06/01/2009 - "There was a significant reduction of organism-mediated pulmonary injury, measured by infarct scores, lung weights, residual fungal burdens, and galactomannan indexes, in AFG5+VRC-treated rabbits versus those treated with AFG5 and VRC alone (P < 0.05). "
01/01/2002 - "CAS improved survival, reduced pulmonary injury, and caused dose-dependent hyphal damage but with no reduction in residual fungal burden or galactomannan antigenemia in persistently neutropenic rabbits with invasive pulmonary aspergillosis."
05/01/2015 - "The bridging study suggested that the "average" patient receiving LAMB at 3 mg/kg/day was predicted to have complete suppression of galactomannan and (1 → 3)-β-D-glucan levels, but 20 to 30% of the patients still had a galactomannan index of >1 and (1 → 3)-β-D-glucan levels of >60 pg/ml. All formulations of amphotericin B induce a dose-dependent reduction in markers of lung injury and circulating fungus-related biomarkers. "
|5.||Sodium Glutamate (Accent)
|6.||Biological Markers (Surrogate Marker)
|8.||Anti-Bacterial Agents (Antibiotics)
|2.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)
|5.||Enteral Nutrition (Feeding, Tube)